ReviewFrontiers in immunology2025
Harnessing oncolytic viruses to overcome immunosuppression in breast cancer: from mechanisms to clinical translation.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic viruses (OVs) possess dual advantages in cancer immunotherapy: they selectively replicate within and lyse tumor cells while simultaneously releasing tumor-associated antigens to recruit and activate immune cells within the local tumor microenvironment (TME), thereby inducing robust and sustained antitumor immunity. Furthermore, these viruses can serve as tumor-targeting vectors for immunomodulation and synergize with other immunotherapeutic approaches. As such, oncolytic virotherapy holds significant potential to overcome the low response rates of breast cancer to existing immunotherapies and expand the therapeutic arsenal. This review systematically elucidates the application and mechanisms of this emerging immunotherapy in addressing the challenges of conventional breast cancer treatments. It also discusses engineering strategies to enhance antitumor immunity, highlights recent preclinical and clinical studies on rational combinations of OVs with other therapies, and outlines current challenges and future prospects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.